Dianthus Therapeutics (DNTH) Competitors $18.75 -0.36 (-1.88%) Closing price 04:00 PM EasternExtended Trading$18.74 -0.01 (-0.05%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH vs. MLTX, IMVT, HCM, AMRX, OGN, MIRM, APLS, VCEL, NAMS, and AAPGShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include MoonLake Immunotherapeutics (MLTX), Immunovant (IMVT), HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), Mirum Pharmaceuticals (MIRM), Apellis Pharmaceuticals (APLS), Vericel (VCEL), NewAmsterdam Pharma (NAMS), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. MoonLake Immunotherapeutics Immunovant HUTCHMED Amneal Pharmaceuticals Organon & Co. Mirum Pharmaceuticals Apellis Pharmaceuticals Vericel NewAmsterdam Pharma Ascentage Pharma Group International MoonLake Immunotherapeutics (NASDAQ:MLTX) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, community ranking, analyst recommendations and dividends. Which has higher earnings and valuation, MLTX or DNTH? MoonLake Immunotherapeutics has higher earnings, but lower revenue than Dianthus Therapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoonLake ImmunotherapeuticsN/AN/A-$36.01M-$2.30-16.76Dianthus Therapeutics$6.52M92.43-$43.56M-$2.88-6.51 Which has more volatility & risk, MLTX or DNTH? MoonLake Immunotherapeutics has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Is MLTX or DNTH more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,250.32%. MoonLake Immunotherapeutics' return on equity of -15.54% beat Dianthus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MoonLake ImmunotherapeuticsN/A -15.54% -15.09% Dianthus Therapeutics -1,250.32%-21.68%-20.88% Do analysts rate MLTX or DNTH? MoonLake Immunotherapeutics presently has a consensus target price of $78.71, suggesting a potential upside of 104.24%. Dianthus Therapeutics has a consensus target price of $53.00, suggesting a potential upside of 182.67%. Given Dianthus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dianthus Therapeutics is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MoonLake Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Does the media favor MLTX or DNTH? In the previous week, MoonLake Immunotherapeutics had 8 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 27 mentions for MoonLake Immunotherapeutics and 19 mentions for Dianthus Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 1.11 beat Dianthus Therapeutics' score of 0.53 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 10 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of MLTX or DNTH? 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 8.2% of Dianthus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community prefer MLTX or DNTH? MoonLake Immunotherapeutics received 44 more outperform votes than Dianthus Therapeutics when rated by MarketBeat users. However, 96.55% of users gave Dianthus Therapeutics an outperform vote while only 82.76% of users gave MoonLake Immunotherapeutics an outperform vote. CompanyUnderperformOutperformMoonLake ImmunotherapeuticsOutperform Votes7282.76% Underperform Votes1517.24%Dianthus TherapeuticsOutperform Votes2896.55% Underperform Votes13.45% SummaryMoonLake Immunotherapeutics beats Dianthus Therapeutics on 11 of the 18 factors compared between the two stocks. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$603M$6.52B$5.37B$8.38BDividend YieldN/A2.65%5.22%4.11%P/E Ratio-7.508.9226.8419.71Price / Sales92.43253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book1.646.466.794.50Net Income-$43.56M$143.98M$3.23B$248.18M7 Day Performance-0.79%3.04%4.07%1.14%1 Month Performance-8.31%7.44%12.52%15.20%1 Year Performance-23.69%-2.46%16.83%6.56% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics1.2703 of 5 stars$18.75-1.9%$53.00+182.7%-24.9%$603M$6.52M-7.5080MLTXMoonLake Immunotherapeutics3.2957 of 5 stars$40.18+4.4%$80.50+100.3%+4.2%$2.57BN/A-31.152Positive NewsAnalyst UpgradeGap UpIMVTImmunovant2.6994 of 5 stars$14.55+3.8%$38.33+163.5%-51.4%$2.47BN/A-5.55120News CoveragePositive NewsGap UpHCMHUTCHMED2.271 of 5 stars$13.92-2.0%$19.00+36.5%-33.9%$2.43B$630.20M0.001,760Positive NewsGap DownAMRXAmneal Pharmaceuticals3.2515 of 5 stars$7.60+2.6%$11.50+51.3%+10.3%$2.36B$2.83B-11.187,600OGNOrganon & Co.4.7544 of 5 stars$8.69-0.2%$18.00+107.1%-59.8%$2.26B$6.29B2.6110,000High Trading VolumeMIRMMirum Pharmaceuticals4.0809 of 5 stars$45.57+2.9%$59.00+29.5%+79.2%$2.25B$379.25M-22.56140News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionAPLSApellis Pharmaceuticals4.1715 of 5 stars$17.52+1.3%$41.37+136.1%-57.2%$2.20B$781.37M-8.63770Gap UpVCELVericel2.5508 of 5 stars$42.65+2.2%$60.86+42.7%-14.9%$2.14B$238.54M710.95300Positive NewsNAMSNewAmsterdam Pharma2.5174 of 5 stars$19.22+4.6%$43.00+123.7%-2.5%$2.11B$45.56M-10.224Gap UpAAPGAscentage Pharma Group InternationalN/A$24.20-0.5%N/AN/A$2.11B$980.65M0.00600Positive NewsGap Up Related Companies and Tools Related Companies MoonLake Immunotherapeutics Alternatives Immunovant Alternatives HUTCHMED Alternatives Amneal Pharmaceuticals Alternatives Organon & Co. Alternatives Mirum Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives Vericel Alternatives NewAmsterdam Pharma Alternatives Ascentage Pharma Group International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNTH) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
